EPC 002
Alternative Names: EPC-002Latest Information Update: 01 Apr 2021
At a glance
- Originator Elpis Biopharmaceuticals
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Glioblastoma; Solid tumours
Most Recent Events
- 18 Mar 2021 EPC 002 is available for licensing as of 18 Mar 2021. https://elpisbiopharmaceuticals.com/partnering/ (Elpis Biopharmaceuticals pipeline, March 2021)
- 01 Mar 2021 Early research in Glioblastoma in USA (Parenteral) (Elpis Biopharmaceuticals pipeline, March 2021)
- 01 Mar 2021 Early research in Solid tumours in USA (Parenteral) (Elpis Biopharmaceuticals pipeline, March 2021)